Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Kelun/Merck Release Positive Early Data on TROP-2 ADC for Gastric Cancer

publication date: Apr 11, 2024

Sichuan Kelun-Biotech and Merck reported preliminary Phase I/II data showing their partnered TROP2-directed ADC produced a promising disease control rate and potential to extend survival in heavily pretreated patients with gastric or gastroesophageal junction cancer. SKB264 achieved a 22% objective response rate in 41 patients while disease control rate was 80.5%, with a median duration of response of 7.5 months. Known as MSD outside of the US, Merck acquired global rights (ex-China) to SKB264 in a $1.4 billion agreement, one of three ADC partnerships (worth up to $12 billion) the two companies formed in 2022. More details....

Stock Symbol: (NYSE: MRK)

Share this with colleagues: